vs
CareDx, Inc.（CDNA）与IONIS PHARMACEUTICALS INC（IONS）财务数据对比。点击上方公司名可切换其他公司
IONIS PHARMACEUTICALS INC的季度营收约是CareDx, Inc.的1.7倍（$203.3M vs $117.7M），CareDx, Inc.净利率更高（2.4% vs -112.8%，领先115.2%），CareDx, Inc.同比增速更快（39.0% vs -10.3%），CareDx, Inc.自由现金流更多（$514.0K vs $-159.0M），过去两年IONIS PHARMACEUTICALS INC的营收复合增速更高（30.4% vs 12.9%）
CareDx是一家专注于器官移植领域的精准医疗企业，核心产品包括移植排斥反应监测诊断试剂、数字健康管理工具及配套临床服务，面向北美和欧洲市场的医疗机构及移植患者，助力提升术后患者生存质量。
IONIS制药是1989年成立的生物科技企业，总部位于美国加利福尼亚州卡尔斯巴德，专注于反义疗法、RNA干扰及CRISPR疗法的研发，2015年12月前曾以Isis制药的名称运营。
CDNA vs IONS — 直观对比
营收规模更大
IONS
是对方的1.7倍
$117.7M
营收增速更快
CDNA
高出49.2%
-10.3%
净利率更高
CDNA
高出115.2%
-112.8%
自由现金流更多
CDNA
多$159.5M
$-159.0M
两年增速更快
IONS
近两年复合增速
12.9%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $117.7M | $203.3M |
| 净利润 | $2.8M | $-229.4M |
| 毛利率 | — | 96.1% |
| 营业利润率 | — | -105.5% |
| 净利率 | 2.4% | -112.8% |
| 营收同比 | 39.0% | -10.3% |
| 净利润同比 | — | -119.8% |
| 每股收益（稀释后） | $0.05 | $-1.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDNAIONS
| Q1 26 | $117.7M | — | ||
| Q4 25 | $108.4M | $203.3M | ||
| Q3 25 | $100.1M | $156.7M | ||
| Q2 25 | $86.7M | $452.0M | ||
| Q1 25 | $84.7M | $131.6M | ||
| Q4 24 | $86.6M | $226.6M | ||
| Q3 24 | $82.9M | $133.8M | ||
| Q2 24 | $92.3M | $225.3M |
净利润CDNAIONS
| Q1 26 | $2.8M | — | ||
| Q4 25 | $-4.1M | $-229.4M | ||
| Q3 25 | $1.7M | $-128.6M | ||
| Q2 25 | $-8.6M | $123.6M | ||
| Q1 25 | $-10.4M | $-146.9M | ||
| Q4 24 | $87.7M | $-104.3M | ||
| Q3 24 | $-10.6M | $-140.5M | ||
| Q2 24 | $-4.6M | $-66.3M |
毛利率CDNAIONS
| Q1 26 | — | — | ||
| Q4 25 | — | 96.1% | ||
| Q3 25 | — | 98.5% | ||
| Q2 25 | — | 99.1% | ||
| Q1 25 | — | 98.9% | ||
| Q4 24 | — | 98.3% | ||
| Q3 24 | — | 99.2% | ||
| Q2 24 | — | 98.2% |
营业利润率CDNAIONS
| Q1 26 | — | — | ||
| Q4 25 | -5.6% | -105.5% | ||
| Q3 25 | -0.2% | -102.2% | ||
| Q2 25 | -12.8% | 30.9% | ||
| Q1 25 | -15.8% | -111.6% | ||
| Q4 24 | 97.5% | -48.9% | ||
| Q3 24 | -16.6% | -111.1% | ||
| Q2 24 | -7.9% | -29.3% |
净利率CDNAIONS
| Q1 26 | 2.4% | — | ||
| Q4 25 | -3.8% | -112.8% | ||
| Q3 25 | 1.7% | -82.1% | ||
| Q2 25 | -9.9% | 27.3% | ||
| Q1 25 | -12.2% | -111.6% | ||
| Q4 24 | 101.3% | -46.1% | ||
| Q3 24 | -12.8% | -105.0% | ||
| Q2 24 | -5.0% | -29.4% |
每股收益（稀释后）CDNAIONS
| Q1 26 | $0.05 | — | ||
| Q4 25 | $-0.08 | $-1.35 | ||
| Q3 25 | $0.03 | $-0.80 | ||
| Q2 25 | $-0.16 | $0.70 | ||
| Q1 25 | $-0.19 | $-0.93 | ||
| Q4 24 | $1.60 | $-0.66 | ||
| Q3 24 | $-0.20 | $-0.95 | ||
| Q2 24 | $-0.09 | $-0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $77.9M | $2.7B |
| 总债务越低越好 | — | $1.8B |
| 股东权益账面价值 | — | $489.1M |
| 总资产 | $411.1M | $3.5B |
| 负债/权益比越低杠杆越低 | — | 3.71× |
8季度趋势，按日历期对齐
现金及短期投资CDNAIONS
| Q1 26 | $77.9M | — | ||
| Q4 25 | $177.2M | $2.7B | ||
| Q3 25 | $194.2M | $2.2B | ||
| Q2 25 | $186.3M | $2.3B | ||
| Q1 25 | $230.9M | $2.1B | ||
| Q4 24 | $260.7M | $2.3B | ||
| Q3 24 | $240.9M | $2.5B | ||
| Q2 24 | $228.9M | $2.1B |
总债务CDNAIONS
| Q1 26 | — | — | ||
| Q4 25 | — | $1.8B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — |
股东权益CDNAIONS
| Q1 26 | — | — | ||
| Q4 25 | $303.1M | $489.1M | ||
| Q3 25 | $311.1M | $618.0M | ||
| Q2 25 | $327.4M | $631.7M | ||
| Q1 25 | $379.3M | $475.7M | ||
| Q4 24 | $378.4M | $588.4M | ||
| Q3 24 | $273.2M | $662.5M | ||
| Q2 24 | $264.7M | $263.7M |
总资产CDNAIONS
| Q1 26 | $411.1M | — | ||
| Q4 25 | $413.2M | $3.5B | ||
| Q3 25 | $432.3M | $3.0B | ||
| Q2 25 | $444.3M | $3.0B | ||
| Q1 25 | $489.6M | $2.8B | ||
| Q4 24 | $491.1M | $3.0B | ||
| Q3 24 | $477.0M | $3.1B | ||
| Q2 24 | $466.8M | $2.7B |
负债/权益比CDNAIONS
| Q1 26 | — | — | ||
| Q4 25 | — | 3.71× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 2.13× | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.3M | $-137.7M |
| 自由现金流经营现金流 - 资本支出 | $514.0K | $-159.0M |
| 自由现金流率自由现金流/营收 | 0.4% | -78.2% |
| 资本支出强度资本支出/营收 | — | 10.5% |
| 现金转化率经营现金流/净利润 | 1.54× | — |
| 过去12个月自由现金流最近4个季度 | — | $-320.0M |
8季度趋势，按日历期对齐
经营现金流CDNAIONS
| Q1 26 | $4.3M | — | ||
| Q4 25 | $21.4M | $-137.7M | ||
| Q3 25 | $37.4M | $-131.4M | ||
| Q2 25 | $9.9M | $151.3M | ||
| Q1 25 | $-26.6M | $-150.8M | ||
| Q4 24 | $21.9M | $-116.1M | ||
| Q3 24 | $12.5M | $-115.0M | ||
| Q2 24 | $18.9M | $-119.9M |
自由现金流CDNAIONS
| Q1 26 | $514.0K | — | ||
| Q4 25 | — | $-159.0M | ||
| Q3 25 | — | $-136.7M | ||
| Q2 25 | — | $139.0M | ||
| Q1 25 | — | $-163.4M | ||
| Q4 24 | — | $-141.6M | ||
| Q3 24 | — | $-124.0M | ||
| Q2 24 | — | $-126.1M |
自由现金流率CDNAIONS
| Q1 26 | 0.4% | — | ||
| Q4 25 | — | -78.2% | ||
| Q3 25 | — | -87.2% | ||
| Q2 25 | — | 30.8% | ||
| Q1 25 | — | -124.1% | ||
| Q4 24 | — | -62.5% | ||
| Q3 24 | — | -92.7% | ||
| Q2 24 | — | -56.0% |
资本支出强度CDNAIONS
| Q1 26 | — | — | ||
| Q4 25 | — | 10.5% | ||
| Q3 25 | — | 3.4% | ||
| Q2 25 | — | 2.7% | ||
| Q1 25 | — | 9.6% | ||
| Q4 24 | — | 11.3% | ||
| Q3 24 | — | 6.8% | ||
| Q2 24 | — | 2.8% |
现金转化率CDNAIONS
| Q1 26 | 1.54× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 22.30× | — | ||
| Q2 25 | — | 1.22× | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDNA
| Testing services revenue | $91.4M | 78% |
| Patient and digital solutions revenue | $16.0M | 14% |
| Product revenue | $10.3M | 9% |
IONS
| Products | $58.0M | 29% |
| Spinraza Royalties | $54.0M | 27% |
| Collaborative Agreement Revenue | $52.4M | 26% |
| Wainus Royalties | $16.0M | 8% |
| Wainua Joint Development Revenue | $9.6M | 5% |
| Other Commercial | $7.6M | 4% |
| Other Royalties | $5.7M | 3% |
